Skip to content
Pharma Observatory a Scientist.com platform

Organization (Other)

Nanfang Hospital

ClinicalTrials.gov lists Nanfang Hospital as lead sponsor of 487 trials. It has 232 active development programs and 110 approved assets.

CN Other
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

87 0 2007 2027

Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.

2026 is partial: 70 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 87 in 2026 and about 77 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (20 to 100), forecasts made part-way through the year were typically off by about 18 percent and ran about 14 percent low against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

This page covers Nanfang Hospital: 487 lead-sponsored trials and 1 legal-entity registration.

Get the Nanfang Hospital report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Disease areas (279)

Shown in this order: most trials first.

Disease areas
Disease area Trials
Head and Neck Neoplasms 42
Colorectal Neoplasms 36
Stomach Neoplasms 35
Hepatitis B 32
Stroke 30

Trials by start year as sponsor or collaborator (20)

Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Show the table of trials by start year as sponsor or collaborator
Trials by start year as sponsor or collaborator
Year Trials started
2026 (partial year) 70
2025 67
2024 78
2023 59
2022 61
2021 47
2020 44
2019 37
2018 51
2017 50

Prediction, not a registry value: median of 36 months from start to primary completion across 52 trials still running at the 2026-10-09 snapshot; registered median of 30 months across 93 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

Active development programs (232)

Shown in this order: max phase, then active trials.

Active development programs
Drug Disease area Max phase Trials
Docetaxel +Cisplatin Nasopharyngeal Neoplasms Phase 3 1
targeted drug Precursor Cell Lymphoblastic Leukemia-Lymphoma Phase 3 1
Docetaxel +Cisplatin Nasopharyngeal Carcinoma Phase 3 1
Docetaxel +Cisplatin Head and Neck Neoplasms Phase 3 1
Docetaxel, Carboplatin Nasopharyngeal Carcinoma Phase 3 1

Approved assets (110)

Shown in this order: max phase first.

Approved assets
Drug Trials
METHOTREXATE 6
G-CSF 5
CYTARABINE 4
ATG 4
Telbivudine 3

Sponsor delivery record (1)

Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.

Sponsor delivery record
Enrollment Timeline
73% hit target (n=44) 35% on time (n=48)

Journals published in (464)

Shown in this order: most published in first.

Journals published in
Journal Publications
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42
The New England journal of medicine 32
The Lancet. Oncology 29
Lancet (London, England) 28
Blood 26

Organization relationships (163)

Shown in this order: most evidence first.

Organization relationships
Related organization Relationship Evidence
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Co sponsors trial with 35
Zhongshan People's Hospital, Guangdong, China Co sponsors trial with 15
West China Hospital Co sponsors trial with 15
Southern Medical University, China Co sponsors trial with 14
Guangdong Second Provincial General Hospital Co sponsors trial with 8

Latest dated events (709)

Shown in this order: newest first.

Latest dated events
Date Event Source
2026-12 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-10-01 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-09-09 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-09 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-09 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))

Biomarker capability evidence (664)

Shown in this order: tier desc, then gene symbol.

Biomarker capability evidence
Gene Role Evidence
ABCB1 Trial sponsor Named in trial inclusion criteria
ABL1 Trial sponsor Named in trial inclusion criteria
ABL1 Trial sponsor Named in trial inclusion criteria
ABL1 Trial collaborator Named in trial inclusion criteria
ABL1 Trial sponsor Named in trial inclusion criteria

Not on this page

Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.